home / stock / alpmy / alpmy news

ALPMY News and Press, Astellas Pharma Inc. ADR From 03/26/19

Stock Information
Company Name: Astellas Pharma Inc. ADR
Stock Symbol: ALPMY
Market: OTC
Menu
ALPMY ALPMY Quote ALPMY Short ALPMY News ALPMY Articles ALPMY Message Board
Get ALPMY Alerts

News, Short Squeeze, Breakout and More Instantly...
ALPMY - Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)

TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced results from a Phase 2b dose-finding study of fezolinetant, presented in an oral session (Abstract OR33-6 ) at ENDO 2019, the Endocr...
ALPMY - Lilly's Cyramza shows positive effect in first-line lung cancer

Results from a Phase 3 clinical trial, RELAY , evaluating Eli Lilly's (NYSE: LLY ) CYRAMZA (ramucirumab) for the first-line treatment of patients with EGFR-positive metastatic non-small cell lung cancer (NSCLC) showed a treatment benefit. More news on: Eli Lilly and Company, Roche Hold...

ALPMY - Astellas teams up with ReForm in alternate dosing of biologics

Astellas Pharma ( OTCPK:ALPMY +0.9% ) will collaborate with Woburn, MA-based ReForm Biologics on reformulating its pipeline of biologic therapies to allow for alternative dosing, specifically subcutaneous injection, more efficient manufacturing and longer product life cycles. More ne...

ALPMY - Keytruda combo therapies show positive effects in prostate cancer study

Preliminary data from an open-label Phase 1b/2 clinical trial, KEYNOTE-365 , evaluating Merck's (NYSE: MRK ) Keytruda (pembrolizumab), combined with various agents, in patients with metastatic castration-resistant prostate cancer (mCRPC) showed a treatment effect across three cohorts. Th...
ALPMY - Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

NEW YORK and TOKYO , Feb. 11, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mH...

ALPMY - IVA Funds Year In Review 2018

Read more ...

ALPMY - Amgen and UCB's Evenity OK'd in Japan for osteoporosis

Japan's Ministry has approved Amgen (NASDAQ: AMGN ) and co-developer UCB's ( OTCPK:UCBJF )( OTCPK:UCBJY ) EVENITY (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture. More news on: Amgen Inc., UCB S.A., UCB S.A. ADR, Healthcare stocks news, Read more ...
ALPMY - Israel's Anchiano Therapeutics files for American-share IPO

Jerusalem-based Anchiano Therapeutics ( OTC:BCNLF ) has filed for an initial public offering of American Depositary Shares. More news on: Anchiano Therapeutics Ltd., Sesen Bio, Inc., Telesta Therapeutics, Inc., Healthcare stocks news, IPO News, Read more ...

ALPMY - Pfizer's Xtandi successful in late-stage study of Xtandi in metastatic prostate cancer

Pfizer ( PFE -0.6% ) and U.S. commercialization partner Astellas Pharma ( OTCPK:ALPMF )( OTCPK:ALPMY )  announce positive results from a Phase 3 clinical trial, ARCHES , evaluating XTANDI (enzalutamide) plus androgen deprivation therapy in men with metastatic hormone-sensitive prost...

ALPMY - Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

TOKYO and NEW YORK , Dec. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating XTANDI ® (enzalutamide) plus androgen deprivation therap...
Previous 10 Next 10